Mesa Considers Next Steps With Pacritinib in Myelofibrosis

Video

Ruben Mesa, MD, spoke about why pacritinib in the treatment of myelofibrosis is beneficial.

Mesa_3
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Ruben Mesa, MD, executive director of Mays Cancer Center, home of the UT Health San Antonio MD Anderson Cancer Center, spoke with CancerNetwork® about future research involving pacritinib (Vonjo) following its accelerated approval in intermediate- or high-risk primary or secondary myelofibrosis with severe thrombocytopenia. Mesa served as lead investigator on the PERSIST-1 trial (NCT01773187), which examined pacritinib in this setting.

      Transcript:

      We now have mature data in terms of what monotherapy with pacritinib looks like in the front-line or second-line setting, particularly for individuals with marked thrombocytopenia. Combination therapies are intriguing, and there are many interesting agents, almost 10 that have a different mechanism of action distinct from JAK2, that are in development. Many of them can cause thrombocytopenia themselves.

      The approval of pacritinib is a significant advance for patients with myelofibrosis. It allows us to create a new group of individuals. Importantly, it also shows that this is a disease where multiple therapies are needed. There is a range of different phenotypes of the disease and many new mechanisms of action are being identified, even with IRAK-1 as an additional important new target. I’m excited to see this advance and excited to see our patients with myelofibrosis [given] more options.

      Reference

      Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225-e236. doi:10.1016/S2352-3026(17)30027-3